XLO
Xilio Therapeutics, Inc. (XLO) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity above revenue suggests a comparatively innovation-heavy footprint, but without emissions or resource-use disclosures XLO cannot be shown to outperform peers on environmental management.
The absence of provided energy, water, waste, and Scope 1–3 data limits evidence of operational efficiency, leaving XLO broadly in line with peers rather than clearly advantaged.
No disclosed environmental targets or transition metrics were provided, so peer-relative assessment remains constrained and does not support a stronger environmental score.
Environmental positioning appears neutral-to-moderate versus peers because available metrics indicate capital allocation discipline, yet they do not directly evidence lower environmental risk.
Social
Stock-based compensation at 12.3% of revenue indicates meaningful employee alignment, but it is not enough on its own to show stronger labor practices than peers.
No workforce, safety, turnover, diversity, or customer-responsibility metrics were provided, limiting evidence that XLO manages social risk better than peers.
The available data do not indicate major social controversies or structural labor issues, so XLO appears broadly average rather than weak on social factors.
Social positioning is modestly supported by compensation alignment, but the lack of broader human-capital disclosure prevents a stronger peer-relative assessment.
Governance
Debt-to-equity of 0.09 suggests conservative balance-sheet governance, which is favorable versus more levered peers and reduces financial oversight risk.
Net debt to EBITDA of 6.33 is elevated, implying weaker leverage discipline than peers and partially offsetting the low debt-to-equity signal.
R&D spending above revenue and moderate stock-based compensation suggest active capital allocation, but the absence of board, audit, and ownership disclosures limits confidence.
Governance is assessed as slightly above average because leverage structure appears disciplined overall, though incomplete disclosure prevents a stronger relative score.
Overall Score
XLO screens as a modestly above-average ESG profile versus peers, with governance and social alignment offset by limited disclosure and no evidence of leading environmental practices.
Score Driver: Conservative Leverage And Compensation Alignment Support The Profile, But Missing ESG Disclosure Prevents A Stronger Peer-Relative Assessment.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Xilio Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
